Silexion Therapeutics Announced New Findings From Its Phase 2 Trial Of LODER In Patients With Non-resectable Locally Advanced Pancreatic Cancer (LAPC) Which Bear KRAS G12D Or G12V Mutation-Filing
Portfolio Pulse from Benzinga Newsdesk
Silexion Therapeutics announced promising results from its Phase 2 trial of LODER for LAPC patients with KRAS mutations, showing a 56% ORR and 67% ORR in patients with resectable tumors.
September 24, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silexion Therapeutics' Phase 2 trial of LODER shows a 56% ORR in LAPC patients, with a 67% ORR in those with resectable tumors, indicating potential for improved surgical outcomes.
The positive trial results for LODER in LAPC patients suggest potential for improved surgical outcomes, which could lead to increased investor confidence and a positive impact on SLXN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100